HDAC9 and prostate cancer: In conclusion, the results described herein reinforce the importance of developing novel multitarget drug candidates structurally designed by combining the pharmacophoric subunits necessary for molecular recognition by the selected targets, in this case, HDAC and PI3K isoforms, to amplify the therapeutic benefits in the treatment of prostate cancer, a multifactorial disease.